Important Safety Information
Clobetasol propionate has been shown to suppress the HPA axis at the lowest doses tested.
Adverse events associated with use of Clobex^® Spray, Lotion and/or Shampoo, (clobetasol propionate 0.05%) include burning/stinging, skin dryness, irritation, erythema, telangiectasia and skin atrophy. In clinical trials, these side effects were typically mild in nature and transient. Clobex^® (clobetasol propionate 0.0.5%) Spray, Lotion and Shampoo are not recommended for use on anyone younger than 18 years of age.

Clobetasol propionate 0.05% should not be used on the face, groin, or axillae, and the total dosage should not exceed 50g (50 mL or 1.75 fl oz of Shampoo or Lotion, or (59 ml or 2 fl oz.) Spray per week. Patients should use Clobex^® Shampoo, 0.05%, Clobex^® Spray, 0.05% or Clobex^® Lotion, 0.05% only for the minimum period necessary to achieve desired results, and treatment beyond 2 weeks in psoriasis should be weighed against the potential risk for HPA axis suppression.

Vectical^® Ointment is indicated for the topical treatment of mild to moderate plaque psoriasis in patients 18 years and older. The most frequent adverse events (≥3%) reported in clinical trials were lab test abnormality, urine abnormality, psoriasis, hypercalciuria, pruritus and skin discomfort. Vectical^® should be used with caution in patients with known or suspected disturbances in calcium homeostasis, who are taking calcium or Vitamin D supplements or who are on diuretics. If aberrations in parameters of calcium metabolism occur, discontinue use until these normalize. Caution patients to avoid excessive exposure to natural or artificial sunlight after applying the ointment. Avoid contact with eyes, lips and face.